mixtard

Novo Nordisk will continue offering its top-selling insulin brand, mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation of widely used insulin products. The company aims to consolidate its insulin portfolio to meet increasing patient demand and ensure a stable medicine supply, focusing on newer treatments.

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectively earned Rs 1,097 crore, with significant launches in cardiac, anti-diabetic, and vitamins sectors, highlighting prevailing health patterns in India.

Call it the Omicron effect. Antibiotic medicine Azithral catapulted to become the largest-selling pharma brand in January for the first time ever, overtaking the market leader anti-diabetic therapy, Human mixtard.

It seems we shrugged off flu as well as virals in April pretty well, as anti-diabetic therapies have started to bounce back, dethroning antibiotics from their pole position.

Call it the Omicron effect. Antibiotic medicine Azithral catapulted to become the largest-selling pharma brand in January for the first time ever, overtaking the market leader anti-diabetic therapy, Human mixtard.

Cough and cold medicines Corex and Phensedyl cough syrups sold the maximum and were among the top five selling brands in the domestic retail market, netting sales of nearly Rs 300 crore during 2008, according to consultancy ORG-IMS.

Call it the Covid effect. Popular health supplement Zincovit, which provides essential vitamins and minerals, catapulted to the top spot in the domestic pharma retail market for the first time ever in October by becoming the largest-selling brand.

Domestic organized pharma retail market crossed Rs 90,000 crore for the first time ever in cumulative sales, driven by a huge growth in sales of anti-diabetic drugs, dermatology and urology medicines.

BANGALORE: The Rs 650-crore Indian insulin market is about to be caught in a price war whirlwind.

The 'pink eye' outbreak has led to a surge in sales of ophthalmology medicine. Sales jumped nearly 30% year-on-year for the second month in a row in August - outgrowing the overall market by almost five times. The rise reflects the massive incidence of conjunctivitis and eye-complications in the last few months across the country.

The domestic pharma sector continued its strong show in 2010 and recorded a 16.5% growth during January-December.

The cough and cold segment led by Phensedyl Linctus and Corex cough syrup were the largest selling category in 2006.

Cough, cold and viral infections did not seem to have bothered us much after the monsoon, as demand for these medicines witnessed a sharp fall during October, leading to a drop in their sales.

There's a new pecking order among top-selling drugs in the nearly Rs 55,000 crore domestic organized retail market .

There's a new pecking order among top-selling drugs in the nearly Rs 55,000 crore domestic organized retail market. Anti-infective medicine Augmentin, till now the fifth largest selling drug, has toppled cough and cold preparation Corex, which was the leading drug for years.

Call it the flu as well as the Covid effect. Antibiotic drug Augmentin has emerged as the largest selling brand in February, overtaking the established market leader for several years now — antidiabetic therapy Human mixtard.

Domestic pharma retail market could be seeing green shoots from now, after plummeting to negative territory in the last two months.

Data suggests that anti-infectives, pain-killers, anti-asthmatics and cough & cold preparations reported lower sales during July perhaps due to lesser spread of infections.

Gastrointestinal drug sales show highest incremental gain in a year for 1st time.

Widely used drug Augmentin occupied the top slot, becoming the largest selling drug in the overall domestic retail market, while multinational company Abbott leapt to the top position with the largest market share for a 12-month period ending April 2011.

The delayed onset of monsoon across the country seems to have dampened medicine sales. The domestic pharma retail market grew 4.5% in June — down from almost 10% growth seen in the previous month. Therapies like respiratory and anti-infectives were in the negative territory, data from IQVIA showed.